Guided View New to genetics? We explain every term as you browse, in plain English. Same pages, with the help built in.
Expert View You already know the biology. Just the content, clean and compact, with no extra explanations. This is the default view.
Interface language
Light mode
CB-010
Treatment · Cancer
CB-010
An allogeneic CAR-T candidate built with hybrid RNA-DNA guides rather than conventional guide RNAs, intended to cut off-target editing.
Phase Icell therapyallogeneicCas12a
Clinical researchBeing tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.
Simple explanation
Caribou builds its edited cells using a modified kind of guide, part RNA and part DNA, which the company says makes the editing machinery fussier about where it cuts. CB-010 is an off-the-shelf CAR-T made this way, with an extra edit that removes a brake on the engineered cells so they keep working longer.
Go deeper
CB-010 is an allogeneic anti-CD19 CAR-T candidate from Caribou Biosciences produced using chRDNA (hybrid CRISPR RNA-DNA) guides with Cas12a, incorporating TRAC insertion of the CAR and PDCD1 knockout to improve persistence. In development for B-cell non-Hodgkin lymphoma and autoimmune indications.
Educational information only
This page is a reference, not medical advice. Research and regulatory status change; check the last-updated date above and confirm anything important against the primary sources listed.
You are leaving CRISPR Decoded
This link opens a website we do not run. We cannot control its content, its accuracy, or how it handles your data, including its own cookies and tracking. Nothing you read there has been reviewed by us.